Cognetivity Neurosciences (CSE: CGN) is expanding its global distribution. The firm this morning announced it has signed a distribution agreement for its medical device product in the Middle East region.
The arrangement will see Emitac Healthcare Solutions become an official distributor of the firms CognICA product. The firm is reportedly a leading provider in the region, having operated in the Middle East for four and a half decades. The firm has major relationships that include Philips Healthcare, Samsung Ultrasound Systems, and the UAE’s Ministry of Health & Prevention.
The arrangement was announced this morning in connection with Arab Health 2022, the largest medical equipment exhibition in the region. The timing is significant, following a recently published study highlighting that the Middle East, particularly the UAE and other gulf nations, are expected to undergo the highest increase globally of people living with dementia by 2050.
The rollout to the region follows the deployment of the device with the United Kingdom’s National Health Service, as well as the Clemenceau Medical Center in Dubai, among other regions.
“We’re delighted to have established this partnership with Emitac Healthcare Solutions. As its list of existing customers and clients shows, Emitac is a hugely-respected name in the region, bringing the experience and the manpower required to service our clientele and reassure customers of our commitment in this market,” commented Dr Sina Habibi, CEO of the company on the development.
Cognetivity Neurosciences last traded at $0.50 on the CSE.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. We may buy or sell securities in the company at any time. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.